Castle Biosciences (CSTL) Gains from Investment Securities (2018 - 2026)

Castle Biosciences has disclosed Gains from Investment Securities across 9 years of filings, most recently posting $24000.0 for Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $24000.0, down 99.05% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.4 million (down 121.96% YoY), and the FY2025 annual result was $119000.0, down 98.64% from the prior year.
• Gains from Investment Securities came in at $24000.0 for Q1 2026 at Castle Biosciences, up from -$4.2 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $9.0 million in Q4 2024 to a low of -$20.4 million in Q2 2022.
• The 5-year median for Gains from Investment Securities is -$151000.0 (2022), against an average of -$1.1 million.
• Across the five-year window, Gains from Investment Securities plunged 26500.0% in 2022 and soared 1735.29% in 2025, its largest moves.
• Castle Biosciences' Gains from Investment Securities stood at -$4.2 million in 2022, then jumped by 98.34% to -$70000.0 in 2023, then soared by 12914.29% to $9.0 million in 2024, then plunged by 146.49% to -$4.2 million in 2025, then jumped by 100.58% to $24000.0 in 2026.
• The last three Gains from Investment Securities figures came in at $24000.0 (Q1 2026), -$4.2 million (Q4 2025), and $4.2 million (Q3 2025), per Business Quant data.